MyChoice test (Myriad Genetics, Salt Lake City, UT, USA), for example, determines HRD status solely in tumor tissues through the combined analyses of pathogenic variants in BRCA1 and BRCA2 based on sequencing and large rearrangements, and by assessing genomic instability in three biomarkers: LOH, telomeric allelic imbalance (TAI), and large-scale state transition (LST) (https://myriad.com/, accessed on 23 November 2021). This evidence concerns the gene BRCA2 and neoplasm.